ELSEVIER

International Journal of Antimicrobial Agents 5 (1995) 271–274

INTERNATIONAL JOURNAL OF
Antimicrobial
Agents

Contents Volume 5

No. 1

Outpatient treatment with parenteral antimicrobial agents
I.M. Hoepelman 1

Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents
D.N. Williams 3

Outpatient parenteral antibiotic therapy
D.M. Poretz 9

The importance of teamwork for outpatient parenteral antibiotic therapy
A.D. Tice 13

Kinetics of antibiotics in relation to effective and convenient outpatient parenteral therapy
W.A. Craig 19

Indications for outpatient treatment with parenteral antibiotics in children
R. Dagan 23

Benefits of outpatient parenteral antibiotic therapy: to the individual, the institution, third-party payers and society
G. Milkovich 27

Outpatient treatment with antimicrobial agents: some management concerns
G.H. Blijham 33

Insurance companies' view on outpatient treatment
J.A.M. van Adrichem 35

Home treatment and reimbursement in The Netherlands
C.A. Postema 39

Quality, costs and cultural beliefs in outpatient treatment with parenteral antibiotics: a comment
G. Schrijvers and B. van der Linden 45

Home care and the general practitioner
E. Schadé 47

The role of the hospital nursing staff in home health-care services
J. van Vliet, R. van Bergen, T. van Boxtel and G. Nieuwland 51

0924-8579/95/$29.00 © 1995 Elsevier Science B.V. All rights reserved

Indications for home intravenous antibiotic therapy in The Netherlands
T.J. Wijlhuizen, C.P.L.C. Van Haaren, P. Vermeij and P.J. Van den Broek 55

Outpatient treatment in the University Hospital Utrecht: organization and infrastructure
P.O. Witteveen 59

Cystic fibrosis and outpatient treatment with parenteral antibiotics in children
J. van der Laag and L. van de Weg 63

Changing health-care systems
B. Holthof 67

No. 2

Antiretroviral drug interactions
E.P. Acosta and C.V. Fletcher 73

Cefotiam hexetil
A. Imada and S. Hirai 85

The worldwide prevalence of methicillin-resistant *Staphylococcus aureus*
A. Voss and B.N. Doebbeling 101

Use of antimicrobial drugs in developing countries
C.M. Kunin 107

Two-hour versus six-hour administration of amphotericin B in the treatment of kala-azar
C.P. Thakur, G.P. Sinha, D. Barat and R.K. Singh 115

Emergence of high-level fluoroquinolone-resistant *Escherichia coli* in Bangladesh
S.K. Saha, M. Hanif, P. Dutta and M.F. Chowdhury 119

Potential of clindamycin in addition to vancomycin for the treatment of oxacillin-resistant *Staphylococcus aureus* septicemia persisting under vancomycin therapy
M. Venditti, P. Baiocchi, C. Santini, P. Galetta, A. Tarasi, C. Brandimarte, P. D'Argenio and P. Campagnano 123

Meropenem: effects on human leukocyte functions and interleukin release
G. Matera, M.C. Berlinghieri and A. Focà 129

Interaction of sub-inhibitory concentrations of ciprofloxacin and rifampicin against *Staphylococcus aureus*
C.J. Coe, S.A. Doss, G.S. Tillotson and S.G.B. Amyes 135

Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg oral dose
J.M. Andrews, R. Wise, D.R. Baldwin and D. Honeybourne 141

No. 3

Azithromycin: the first of the tissue-selective azalides
I.M. Hoepelman and M.M.E. Schneider 145

A critical review of the in-vitro activity of teicoplanin
R.C. Spencer and R. Goering 169

Antibiotic resistance of bacterial strains isolated from children in Child Health Center, Warsaw
D. Dzierżanowska, U. Łopaciuk, W. Kamińska, J. Wieczyńska, A. Pawińska and J. Patzer 179

In vitro activity of loracarbef against common respiratory pathogens compared with amoxicillin-clavulanic acid: a multi-centre study in The Netherlands
A.J.A. van Griethuysen, A.J.H.M. Janssen, M. van Noort, H.A. Verbrugh and R.J.A. Diepersloot 183

Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial
L.O. Neville, W. Brumfitt, J.M.T. Hamilton-Miller and I. Harding 187

Cefotaxime-resistant Gram-negative bacilli in a University Hospital: occurrence, identity, source and sensitivity patterns
J.M.T. Hamilton-Miller and C. Smith 195

Sequences related to Tn*1331* associated with multiple antimicrobial resistance in different *Salmonella* serovars
D. Centrón García, M. Woloj, S. Kaufman, D.O. Sordelli and S. Piñeiro. 199

No. 4

Brucellosis
R. Lang, M. Banai, M. Lishner and E. Rubinstein 203

Pharmacology and clinical use of foscarnet
L. Gérard and D. Salmon-Céron 209

Itraconazole for the treatment of histoplasmosis and blastomycosis
J.E. Mangino and P.G. Pappas 219

Arbekacin
Y. Kobayashi, H. Uchida and Y. Kawakami 227

Oral cephalosporins: current perspectives
J.A. García-Rodríguez, J.L. Muñoz Bellido and J.E. García Sánchez 231

Quality and bioavailability of tetracycline capsules in a Nigerian semi-urban community
I.N. Okeke and A. Lamikanra 245

In vitro activity of WY-49605, a penem antimicrobial
G.M. Eliopoulos, C.B. Wennersten, G. Cole and R.C. Moellering, Jr. 251

A study of the interaction between recombinant bactericidal permeability increasing protein ($rBPI_{23}$) and gentamicin
N.J. Saunders and J. Cohen 259

Book Review 265

Author Index 267

Contents Volume 5 271